- Trial Phase
- Phase 1/2 (estimated — Phase 2 topline data expected H2 2028)
- Time to Market
- Unknown — Phase 2 data not expected until H2 2028, putting potential approval several years beyond that if results are positive.
- Why 4/10
- RXC008's next hard, dated catalyst is Phase 2 topline data expected H2 2028 — more than 12 months out — so per the rubric the impact score cannot exceed 5. The drug is mid-stage with no near-term binary event, and the company is undergoing a transformative reverse merger that shifts focus away from its legacy pipeline.
For SKYE shareholders, the value thesis has been fundamentally altered by the Redx reverse merger — existing holders are being diluted to ~5.38% ownership. RXC008's next meaningful catalyst (Phase 2 topline data) is not expected until H2 2028, roughly two years out. Investors should assess whether the CVRs offered to legacy SKYE holders have any real value and monitor the shareholder vote on the merger.
Price Chart
Executive Summary
RXC008 is a fibrosis drug candidate from private UK biotech Redx Pharma, which is being acquired by Skye Bioscience (SKYE) in a reverse merger that will form a new entity called Fibrx Therapeutics. The combined company has secured $125M in committed financing to advance RXC008 through Phase 2 topline data expected in H2 2028. However, pre-transaction Skye shareholders will own only ~5.38% of the combined company, representing extreme dilution. The drug is still in early-to-mid stage development with no near-term binary catalyst, and the reverse merger structure heavily disadvantages current SKYE holders.
How It Works
RXC008 is an oral drug candidate designed to treat fibrotic diseases — conditions where excessive scar tissue builds up in organs like the lungs or liver, stiffening them and impairing function. It targets fibrosis through a mechanism developed by Redx Pharma, though the specific molecular target has not been publicly confirmed in available filings.
Trial Status
RXC008 is being funded through Phase 2 development with $125M in committed financing from the Redx reverse merger. Phase 2 topline data is expected in the second half of 2028. No clinical trial records for RXC008 were found in the SecBot database, suggesting it is still in early-stage or preparatory phases.
The Two-Sided Case
Upcoming Catalysts
- Reverse merger closing (shareholder vote pending) — near-term catalyst but not drug-specific
- Phase 2 topline data expected H2 2028
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Skye Bioscience, Inc. Press Release SKYE ·Originating report